Welcome to our dedicated page for Traws Pharma SEC filings (Ticker: TRAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Traws Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Traws Pharma's regulatory disclosures and financial reporting.
Traws Pharma, Inc. reported that on July 29, 2026 it received a notification letter from the Nasdaq Listing Qualifications Department stating that its common stock is not in compliance with the Nasdaq Capital Market minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), because the closing bid price has been below $1.00 per share for at least 30 consecutive business days. The notice does not immediately affect the company’s Nasdaq listing.
Traws Pharma has 180 calendar days, until January 25, 2027, to regain compliance, which requires a closing bid price at or above $1.00 per share for at least 10 consecutive business days, a period Nasdaq may extend to up to 20 days. If compliance is not regained, Nasdaq may grant a second 180‑day grace period if other listing standards are met and the company plans to cure the deficiency. Otherwise, the stock may be subject to delisting, which the company could appeal. Traws Pharma states it will monitor its bid price and consider options, but there is no assurance of regaining compliance.
Traws Pharma, Inc. reported a compensation-related insider transaction for Chief Science Officer Virology Charles David Pauza. He received a grant of 97,000 stock options on July 9, 2026, with an exercise price of $0.68 per share, vesting 100% on July 9, 2027 and expiring July 9, 2036. Following the award, he directly holds options for 97,000 underlying shares of common stock.
Traws Pharma, Inc. director Werner Cautreels received a grant of stock options to acquire 14,150 shares of common stock at an exercise price of $0.68 per share. The options, granted on July 9, 2026 under the 2021 Incentive Compensation Plan, vest 100% after one year and expire on July 9, 2036, leaving him holding options for 14,150 shares directly.
Traws Pharma, Inc. reported that Chief Operating Officer Nikolay Savchuk received a grant of stock options covering 93,000 shares of common stock on July 9, 2026. The options have an exercise price of $0.68 per share, expire on July 9, 2036, and vest 100% on the first anniversary of the grant date.
Traws Pharma, Inc. director Jack E. Stover received a grant of stock options for 14,150 shares of common stock on July 9, 2026. The options have a $0.68 exercise price, were awarded under the 2021 Incentive Compensation Plan, and were granted at $0.00 per option as compensation. They vest 100% on the first anniversary of the grant date and expire on July 9, 2036. Following this award, Stover directly holds options covering 14,150 shares.
Traws Pharma, Inc. granted its Chief Executive Officer and director, Iain D. Dukes, stock options covering 274,000 shares of common stock with an exercise price of $0.68 per share under its 2021 Incentive Compensation Plan.
The options vest 100% on the first anniversary of the July 9, 2026 grant date and expire on July 9, 2036, leaving Dukes holding 274,000 options following this award.
Traws Pharma, Inc. granted Chief Medical Officer Robert Redfield a stock option award covering 84,000 shares of common stock. The options have an exercise price of $0.68 per share and expire on 2036-07-09. The award was granted at a transaction price of $0.00 per option under the company’s 2021 Incentive Compensation Plan, as amended. According to the award terms, the options will vest 100% on the first anniversary of the 2026-07-09 grant date. Following this grant, Redfield directly holds options for 84,000 underlying shares.
Traws Pharma, Inc. reported that Chief Financial Officer Parker Charles Nolan received a grant of 90,000 stock options to purchase common stock. The options have an exercise price of $0.68 per share, vest 100% on the first anniversary of the July 9, 2026 grant date, and expire on July 9, 2036. The award was approved by the compensation committee of independent directors under the company’s 2021 Incentive Compensation Plan. Following this grant, Nolan holds 90,000 stock options directly.
Traws Pharma director Mary Teresa Shoemaker received a grant of stock options for 14,150 shares of common stock on July 9, 2026 at an exercise price of $0.68 per share. Granted under the 2021 Incentive Compensation Plan, the options vest 100% on the first anniversary of the grant date and expire on July 9, 2036, and are held directly.
Traws Pharma, Inc. director Clarke Trafford received a grant of stock options to purchase 14,150 shares of common stock at an exercise price of $0.68 per share. The options were awarded under the company’s 2021 Incentive Compensation Plan, vest 100% one year after the grant date, and expire on July 9, 2036, leaving Trafford with 14,150 options following the award.